Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Advitech Solutions Reports Positive Interim Results on Novel Compound for Psoriasis - Nutraceuticals World

What are you searching for?

Sign in
Research

Advitech Solutions Reports Positive Interim Results on Novel Compound for Psoriasis

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Advitech Solutions has published interim results for its ongoing open label clinical study for a psoriasis treatment based on its XP-828L product, a mix of growth factors extracted from whey protein. The main objectives of the study are to determine the safety and efficacy of the XP-828L, an oral treatment for psoriasis. Eleven patients were recruited for an initial eight-week study, and eight out of the 11 accepted to continue for an eight-week extension period. After the initial eight-week study, seven patients of 11, or 64%, showed a reduction in their psoriasis area and severity index (PASI) score compared with their baseline PASI score at day one; three have remained stable and the PASI score has increased for one patient. Safety data collected for all patients have shown no adverse reactions related to the use of the XP-828L product.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters